Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹5 Cr
Revenue (TTM)
₹1 Cr
Net Profit (TTM)
₹-4 Cr
ROE
-47.9 %
ROCE
-33.8 %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
-15.9
Div. Yield
0 %
Debt to Equity
0.3
Book Value
₹1.1
EPS
₹-0.7
Face value
2
Shares outstanding
55,562,000
CFO
₹-3.55 Cr
EBITDA
₹-7.67 Cr
Net Profit
₹-11.35 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zyden Gentec
| -17.1 | -8.4 | -13.0 | -20.2 | -50.5 | -21.9 | -26.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
BSE Healthcare#
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2015
|
2014
|
|---|---|---|
|
Zyden Gentec
| -27.5 | -56.8 |
|
BSE Sensex
| -5.0 | 29.9 |
|
BSE Healthcare
| 15.1 | 47.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zyden Gentec
|
0.9 | 4.8 | 1.2 | -3.8 | -- | -47.9 | -- | 0.4 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Zyden Gentec Limited, a pharmaceutical company, manufactures and sells drug intermediates in India. It also designs, develops, patents, manufactures, and sells drugs, chemicals, and compounds. The company was incorporated in 1994 and is based in... Secunderabad, India. Read more
Incorporated
1994
Chairman
--
Managing Director
Vinod Shiv Kumar Gupta
Headquarters
Kota, Rajasthan
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsFinancial Results for December 31, 2015
22-Feb-2016Financial Results for Sept 30, 2015 (Clear Copy)
01-Jan-2016Financial Results for Sept 30, 2015 (Standalone)
14-Nov-2015Shareholding Pattern for September 30, 2015
13-Oct-2015Board Meeting on Sept 18, 2015
11-Sep-2015Financial Results for June 30, 2015
14-Aug-2015
The share price of Zyden Gentec Ltd is ₹0.87 (BSE) as of 28-Mar-2016 IST. Zyden Gentec Ltd has given a return of -50.54% in the last 3 years.
Since, TTM earnings of Zyden Gentec Ltd is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2019
|
0.00
|
0.00
|
|
2018
|
0.00
|
0.00
|
|
2017
|
0.00
|
0.00
|
|
2016
|
0.00
|
0.40
|
|
2015
|
0.00
|
0.48
|
The 52-week high and low of Zyden Gentec Ltd are Rs -- and Rs -- as of 04-Apr-2026.
Zyden Gentec Ltd has a market capitalisation of ₹ 5 Cr as on 28-Mar-2016. As per SEBI classification, it is a company.
Before investing in Zyden Gentec Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.